Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 03, 2015 4:46 AM ET

Healthcare Equipment and Supplies

Company Overview of Singulex, Inc.

Company Overview

Singulex, Inc. develops and manufactures immunodiagnostic products. It provides immunoassay systems, which includes benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and software to automatically analyze data and display detailed assay reports. The company also offers molecule counting products; ultrasensitive immunoassays, such as inflammation, cardiovascular, neurology, oncology, metabolism, and toxicity; SgxHD for cardiovascular monitoring; and custom services and support, such as sample testing, assay development, and antibody derivatization. Singulex, Inc. was formerly known as BioProfile Corporation and changed its name to Singulex, ...

1650 Harbor Bay Parkway

Suite 200

Alameda, CA 94502

United States

Founded in 1997

177 Employees

Phone:

510-995-9000

Fax:

510-995-9092

Key Executives for Singulex, Inc.

Chief Executive Officer, President and Director
Age: 50
Chief Financial Officer and Principal Accounting Officer
Age: 46
Chief Commercial Officer and Senior Vice President of Sales & Marketing
Age: 63
Chief Medical Officer
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Singulex, Inc. Key Developments

Merck Millipore Enters into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting Technology

Merck Millipore and Singulex announced that they have entered into a definitive agreement under which Merck Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, Merck Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. Merck Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide. Reliable, ultra-sensitive protein detection is a critical unmet need in life science research. Current technologies allow detection of only approximately 5% of proteins in the entire proteome due to the very low abundance of many biomarkers, leaving the vast majority of proteins virtually undetectable. The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits of this technology have been well-established and Singulex will continue to operate a large and successful clinical service business based on novel, enabling SMC assays. Financial and other terms of the deal were not disclosed.

Singulex Announces Collaboration with CHDI Foundation to Develop Biomarker Assays for Huntington's Disease

Singulex, Inc. announced a collaboration agreement with CHDI Foundation. The collaboration will use Singulex's proprietary Erenna Immunoassay System to develop biomarkers to further Huntington's disease research. The Singulex assay combines fluorescent antibodies with a laser detection chamber to count individual molecules of mHTT with a very low detection threshold, including both high specificity for mHTT and sensitivity to the femtomolar level.

Health Diagnostics Laboratory Inc and Singulex, Inc. Labs to Pay $48.5 Million to Settle Doctor's Whistleblower Case

Health Diagnostics Laboratory Inc. and Singulex Inc. have agreed to resolve allegations that they violated the False Claims Act by paying remuneration to physicians in exchange for patient referrals and billing federal health care programs for medically unnecessary testing, the U.S. Department of Justice. Under the settlements, which stem from three related whistleblower actions filed under the federal False Claims Act, HDL will pay $47 million and Singulex will pay $1.5 million.

Similar Private Companies By Industry

Company Name Region
Del Medical Inc. United States
Cameron Health, Inc. United States
Pulmonetic Systems, Inc. United States
Convergent Laser Technologies United States
Ironwood Material Science, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 21, 2015
Singulex, Inc., Singulex Life Science Research Business
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Singulex, Inc., please visit www.singulex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.